Gyre Therapeutics (GYRE) Free Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.26% |
| Dec 31, 2025 | 23.63% |
| Sep 30, 2025 | 18.10% |
| Jun 30, 2025 | 16.26% |
| Mar 31, 2025 | 44.59% |
| Dec 31, 2024 | 19.74% |
| Sep 30, 2024 | 16.15% |
| Jun 30, 2024 | 9.61% |
| Mar 31, 2024 | 16.84% |
| Dec 31, 2023 | 16.14% |
| Sep 30, 2023 | 22.85% |
| Jun 30, 2023 | 17.89% |
| Mar 31, 2023 | 29.45% |
| Dec 31, 2022 | 54.05% |
| Sep 30, 2022 | -8.10% |
| Jun 30, 2022 | -22.80% |
| Mar 31, 2022 | -22.91% |
| Dec 31, 2021 | -28.23% |
| Sep 30, 2021 | -33.91% |
| Jun 30, 2021 | -39.01% |
| Mar 31, 2021 | -38.19% |
| Dec 31, 2020 | -33.37% |
| Sep 30, 2020 | -6.52% |
| Jun 30, 2020 | -61.79% |
| Mar 31, 2020 | -10.04% |
| Dec 31, 2019 | -31.47% |
| Sep 30, 2019 | -19.81% |
| Jun 30, 2019 | -5.26% |
| Mar 31, 2019 | -0.17% |
| Dec 31, 2018 | -19.09% |
| Sep 30, 2018 | 6.27% |
| Jun 30, 2018 | 6.61% |
| Mar 31, 2018 | 10.79% |
| Dec 31, 2017 | 11.69% |
| Sep 30, 2017 | 13.88% |
| Jun 30, 2017 | 24.06% |
| Mar 31, 2017 | 29.66% |
| Dec 31, 2016 | 24.50% |
| Sep 30, 2016 | 22.41% |
| Jun 30, 2016 | 30.25% |
| Mar 31, 2016 | 26.57% |
| Dec 31, 2015 | 21.27% |
| Sep 30, 2015 | 10.94% |